Toxicities of Anti-PD-1/PD-L1 Immune Checkpoint Antibodies

Toxicities
 Abstract and Introduction

• General Adverse Events of Anti-PD-1/PD-l1 Therapy
• Organ-specific Adverse Events With Single-agent Anti-PD-1/PD-l1 Agents
• Rare Toxicities With Anti-PD-1/PD-L1 Agents
• Combinations of Anti-PD-1/PD-l1 Agents With Other Anticancer Agents
• Anti-PD-1/PD-l1 Therapy in Patients With Pre-existing Autoimmune or Infectious Diseases
• Conclusion

• References